Hatter Institute for Cardiovascular Research in Africa, Department of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa.
Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
Eur J Heart Fail. 2017 Sep;19(9):1131-1141. doi: 10.1002/ejhf.780. Epub 2017 Mar 8.
The purpose of this study is to describe disease presentation, co-morbidities, diagnosis and initial therapeutic management of patients with peripartum cardiomyopathy (PPCM) living in countries belonging to the European Society of Cardiology (ESC) vs. non-ESC countries.
Out of 500 patients with PPCM entered by 31 March 2016, we report on data of the first 411 patients with completed case record forms (from 43 countries) entered into this ongoing registry. There were marked differences in socio-demographic parameters such as Human Development Index, GINI index on inequality, and Health Expenditure in PPCM patients from ESC vs. non-ESC countries (P < 0.001 each). Ethnicity was Caucasian (34%), Black African (25.8%), Asian (21.8%), and Middle Eastern backgrounds (16.4%). Despite the huge disparities in socio-demographic factors and ethnic backgrounds, baseline characteristics are remarkably similar. Drug therapy initiated post-partum included ACE inhibitors/ARBs and mineralocorticoid receptor antagonists with identical frequencies in ESC vs. non-ESC countries. However, in non-ESC countries, there was significantly less use of beta-blockers (70.3% vs. 91.9%) and ivabradine (1.4% vs. 17.1%), but more use of diuretics (91.3% vs. 68.8%), digoxin (37.0% vs. 18.0%), and bromocriptine (32.6% vs. 7.1%) (P < 0.001). More patients in non-ESC vs. ESC countries continued to have symptomatic heart failure after 1 month (92.3% vs. 81.3%, P < 0.001). Venous thrombo-embolic events, arterial embolizations, and cerebrovascular accidents were documented in 28 of 411 patients (6.8%). Neonatal death rate was 3.1%.
PPCM occurs in women from different ethnic backgrounds globally. Despite marked differences in socio-economic background, mode of presentation was largely similar. Embolic events and persistent heart failure were common within 1 month post-diagnosis and required intensive, multidisciplinary management.
本研究旨在描述欧洲心脏病学会(ESC)成员国与非 ESC 成员国的围产期心肌病(PPCM)患者的疾病表现、合并症、诊断和初始治疗管理。
在 2016 年 3 月 31 日前纳入的 500 例 PPCM 患者中,我们报告了该正在进行的登记研究中已完成病例报告表的前 411 例患者的数据(来自 43 个国家)。ESC 与非 ESC 国家的 PPCM 患者在社会人口统计学参数(如人类发展指数、不平等基尼指数和卫生支出)方面存在显著差异(均<0.001)。种族为白种人(34%)、黑非洲人(25.8%)、亚洲人(21.8%)和中东人(16.4%)。尽管社会人口学因素和种族背景存在巨大差异,但基线特征非常相似。产后开始的药物治疗包括 ACE 抑制剂/ARB 和盐皮质激素受体拮抗剂,在 ESC 与非 ESC 国家的使用频率相同。然而,在非 ESC 国家,β受体阻滞剂(70.3%对 91.9%)和伊伐布雷定(1.4%对 17.1%)的使用明显减少,但利尿剂(91.3%对 68.8%)、地高辛(37.0%对 18.0%)和溴隐亭(32.6%对 7.1%)的使用增加(均<0.001)。非 ESC 国家的患者在 1 个月后继续有症状性心力衰竭的比例高于 ESC 国家(92.3%对 81.3%,P<0.001)。在 411 例患者中有 28 例(6.8%)发生静脉血栓栓塞事件、动脉栓塞和脑血管意外。新生儿死亡率为 3.1%。
PPCM 发生在全球不同种族背景的女性中。尽管社会经济背景存在显著差异,但表现模式基本相似。在诊断后 1 个月内,栓塞事件和持续性心力衰竭较为常见,需要强化的多学科管理。